{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+for+SAD",
    "query": {
      "intervention": "Placebo for SAD"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 154,
    "total_pages": 16,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+for+SAD&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-05T04:17:51.302Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06345755",
      "title": "A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Autosomal Dominant Polycystic Kidney Disease (ADPKD)"
      ],
      "interventions": [
        {
          "name": "VX-407",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vertex Pharmaceuticals Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 159,
      "start_date": "2024-04-17",
      "completion_date": "2025-06-13",
      "has_results": false,
      "last_update_posted_date": "2025-07-14",
      "last_synced_at": "2026-09-05T04:17:51.302Z",
      "location_count": 1,
      "location_summary": "Lenexa, Kansas",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06345755"
    },
    {
      "nct_id": "NCT07169279",
      "title": "Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Achondroplasia"
      ],
      "interventions": [
        {
          "name": "Infigratinib is provided as a single dose of minitablets for oral administration",
          "type": "DRUG"
        },
        {
          "name": "Infigratinib is provided as sprinkle capsules for daily oral administration",
          "type": "DRUG"
        },
        {
          "name": "Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "QED Therapeutics, a BridgeBio company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "32 Months",
        "sex": "ALL",
        "summary": "0 Years to 32 Months"
      },
      "enrollment_count": 77,
      "start_date": "2025-11-19",
      "completion_date": "2032-03",
      "has_results": false,
      "last_update_posted_date": "2026-07-13",
      "last_synced_at": "2026-09-05T04:17:51.302Z",
      "location_count": 3,
      "location_summary": "Oakland, California • Baltimore, Maryland • Madison, Wisconsin",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07169279"
    },
    {
      "nct_id": "NCT07223216",
      "title": "Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "BMF-650",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biomea Fusion Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 80,
      "start_date": "2025-10-23",
      "completion_date": "2026-06",
      "has_results": false,
      "last_update_posted_date": "2026-04-09",
      "last_synced_at": "2026-09-05T04:17:51.302Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07223216"
    },
    {
      "nct_id": "NCT07024602",
      "title": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ASC50 Tables in Healthy Participants and Participants With Plaque Psoriasis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Plaque Psoriasis"
      ],
      "interventions": [
        {
          "name": "ASC50 tablets or matching placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ascletis Pharma (China) Co., Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 94,
      "start_date": "2025-06",
      "completion_date": "2026-06",
      "has_results": false,
      "last_update_posted_date": "2025-06-17",
      "last_synced_at": "2026-09-05T04:17:51.302Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07024602"
    },
    {
      "nct_id": "NCT06394167",
      "title": "A Phase 1 Dose Escalation Study of Intravenous VX-993 in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pain"
      ],
      "interventions": [
        {
          "name": "VX-993",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vertex Pharmaceuticals Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 88,
      "start_date": "2024-05-09",
      "completion_date": "2025-02-18",
      "has_results": false,
      "last_update_posted_date": "2025-03-20",
      "last_synced_at": "2026-09-05T04:17:51.302Z",
      "location_count": 1,
      "location_summary": "Lenexa, Kansas",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06394167"
    },
    {
      "nct_id": "NCT01712321",
      "title": "Study of Vilazodone to Treat Social Anxiety Disorder",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Social Anxiety Disorder"
      ],
      "interventions": [
        {
          "name": "Vilazodone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Medical Research Network",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 30,
      "start_date": "2012-10",
      "completion_date": "2014-04",
      "has_results": false,
      "last_update_posted_date": "2014-01-20",
      "last_synced_at": "2026-09-05T04:17:51.302Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01712321"
    },
    {
      "nct_id": "NCT01591668",
      "title": "A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "Single Ascending Dose Cohorts GS-9620",
          "type": "DRUG"
        },
        {
          "name": "Multiple Ascending Dose Cohorts GS-9620",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 51,
      "start_date": "2012-03",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2013-08-13",
      "last_synced_at": "2026-09-05T04:17:51.302Z",
      "location_count": 10,
      "location_summary": "Little Rock, Arkansas • DeLand, Florida • Orlando, Florida + 7 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Berlin",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01591668"
    },
    {
      "nct_id": "NCT07363395",
      "title": "Safety, Tolerability, and Pharmacokinetics of ASCT-83 in Healthy Adults",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neuropathic Pain"
      ],
      "interventions": [
        {
          "name": "ASCT-83",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alcamena Stem Cell Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 72,
      "start_date": "2026-01-06",
      "completion_date": "2026-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-16",
      "last_synced_at": "2026-09-05T04:17:51.302Z",
      "location_count": 1,
      "location_summary": "Saint Paul, Minnesota",
      "locations": [
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07363395"
    },
    {
      "nct_id": "NCT06562907",
      "title": "Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Weight Management"
      ],
      "interventions": [
        {
          "name": "GS-4571",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Omeprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 134,
      "start_date": "2024-08-28",
      "completion_date": "2026-11",
      "has_results": false,
      "last_update_posted_date": "2026-06-22",
      "last_synced_at": "2026-09-05T04:17:51.302Z",
      "location_count": 3,
      "location_summary": "Miami, Florida • San Antonio, Texas • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06562907"
    },
    {
      "nct_id": "NCT04815551",
      "title": "A Phase 1 Study of AV-380 in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cachexia"
      ],
      "interventions": [
        {
          "name": "AV-380",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AVEO Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 51,
      "start_date": "2021-02-22",
      "completion_date": "2022-01-14",
      "has_results": false,
      "last_update_posted_date": "2023-06-12",
      "last_synced_at": "2026-09-05T04:17:51.302Z",
      "location_count": 1,
      "location_summary": "Newark, New Jersey",
      "locations": [
        {
          "city": "Newark",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04815551"
    }
  ]
}